NCT01248988View on ClinicalTrials.gov

Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea

CompletedOBSERVATIONAL
Enrollment

622

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Infections, Streptococcal
Interventions
OTHER

Synflorix™ Data collection

Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.

Trial Locations (1)

443-721

GSK Investigational Site, Suwon, Kyonggi-do

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01248988 - Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea | Biotech Hunter | Biotech Hunter